Home > Press release

Autorizzo al trattamento dei miei dati personali
ai sensi del D.L. 30 giugno 2003 n. 196
Edit email address
Invalid email
Your request has been sent successfully
Authorize the processing of personal data
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category
Restore to Impact | Award Ceremony
Chiesi explores the impact of climate change on people living with respiratory conditions in the series “The Climate and Us”
Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis
Chiesi Group Partnership Day 2023
Chiesi Global Rare Diseases Releases Report on the Burden of Care for Rare Diseases and Its Economic Impact on European Citizens
Chiesi Foundation’s NEST Partners Meeting in Sub-Saharan Africa
Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health to Overall Well-Being, New Report Warns
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
Chiesi Group mid-year financial results demonstrate strong growth for 2023
Chiesi's Sustainability Report 2022: a year of tangible achievements for patients, communities, and the planet
Alessandro Chiesi appointed Chair of the Chiesi Group
Maria Paola Chiesi becomes the Vice Chair
Chiesi at EPNS 2023 to confirm its commitment on alpha-mannosidosis with the projection of the movie “Rare Land” and the presentation of 4 posters
Chiesi Global Rare Diseases Announces FDA Approval of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Chiesi Global Rare Diseases Announces European Commission (EC) Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
2022 for Chiesi: The Group’s international growth continues
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
Restore to Impact - The next healthcare landmark for innovation and future-oriented competencies
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease
Chiesi Global Rare Diseases Presents Long-Term Results from Phase 3 BALANCE and BRIGHT Studies in Fabry Disease at the 19th Annual WORLDSymposium™ Research Meeting
Chiesi Global Rare Diseases Announces FDA Approval of Lamzede® (velmanase alfa-tycv) for Alpha-Mannosidosis
Chiesi appoints Giuseppe Accogli as new Group CEO
Important recognitions for Chiesi Group from the Carbon Disclosure Project (CDP) and Cerved Rating Agency
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Group communicates that it is not involved in the events concerning the Holostem company
Chiesi Group endorses the Manifesto Against Gender-Based Violence
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma
Chiesi Group and Aptar partner to bring to market Disease Management Platform for Patients with Asthma and COPD
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
First carbon minimal pMDI is on track with the goal to benefit patients and planet
Chiesi tracks actions taken for a healthier, more sustainable future
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
Solidarity actions to support the people affected by the war
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
Chiesi Group continues to grow
Koura opens world’s first HFA 152a medical propellant production facility
Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
A new clinical framework redefines the diagnosis of COPD Exacerbations
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
Chiesi Group Headquarters takes centre stage in the monograph “SPAZIO LAVORO ARCHITETTURA” (SPACE WORK ARCHITECTURE) Electaarchitettura editions
Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
Chiesi Research Centre: 10 years’ scientific innovation serving the community
Chiesi receives positive ESG rating from independent rating agency Cerved
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Chiesi Group calls for #ActionOverWords in the fight against climate change
New organisational order for the Chiesi Foundation
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
Chiesi Group: performance is up in 2020
Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support
Chiesi Group receives the European marketing authorisation for Trimbow® (beclometasone dipropionate, formoterol fumarate, glycopyrronium) an extrafine formulation fixed triple combination therapy for the treatment of asthma
Chiesi Headquarters: an innovative, sustainable and people-friendly “home”, the first building in its category to be certified “LEED Platinum” in Italy. A people-oriented project.
“Infermieri, a viso aperto”, a photographic project bringing to light the faces and stories of those who help patients every day
Kaia Health and Chiesi Group Announce Strategic Partnership to Commercialise Kaia COPD Pulmonary Rehabilitation App in European Markets
Chiesi Group receives Diversity Leaders Award 2021
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
Maria Paola Chiesi received by the President of the Italian Republic for the 2020 Bellisario Award ceremony
We ACT Day 2020: the third edition of Chiesi’s event for a sustainable future
Chiesi Farmaceutici President appointed Knight of the Légion d’Honneur
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi Group confirmed Top Employer 2020 in Italy and Europe
Chiesi Group sponsors Parma Capital of Culture 2020
Chiesi Group joins the Cooperative Compliance Programme run by the Italian Revenue Agency
Chiesi outlines €350 million investment and announces first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
Chiesi Group receives Diversity Leaders Award 2020
We ACT Day 2019: Chiesi sets itself the challenge of becoming carbon neutral by 2035
Chiesi Group confirms positive trend to date for 2019
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
Paolo Chiesi appointed Honorary Doctor at Karolinska Institutet
Chiesi Group receives the EURORDIS Black Pearl Award for innovation in the field of Rare Disease.
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
COPD, a disease still underestimated by Europeans: absence of perceived risk, according to Eurisko survey.
Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.
Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa)
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
Chiesi Group receives the European Marketing Authorisation for Lamzede®▼(velmanase alfa)
Chiesi hosts groundbreaking ceremony for the Group’s future Headquarters
New study published in The Lancet shows Trimbow® (beclometasone/formoterol/glycopyrronium) superiority over Ultibro® Breezhaler® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi Group confirmed Top Employer 2018 in Italy and Europe
Chiesi Group receives positive opinion from CHMP for Lamzede® (velmanase alfa), the first therapy for Alpha-Mannosidosis
The Chiesi Group is one of the 8 Italian companies invited by Macron to the French International Summit in Versailles
Chiesi is the first Italian pharmaceutical Company for investments in Research and Development
TRIBUTE study shows superiority of Chiesi's Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Trimbow® is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence
Glybera▼ (alipogene tiparvovec) in Europe
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
GOLD 2017 Report: Chiesi Farmaceutici highlights relevant gaps
Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
Chiesi Farmaceutici is the first company to submit a marketing authorisation application to the European Medicine Agency for a Triple Combination for the treatment of COPD
The Lancet publishes the results of Chiesi Farmaceutici TRILOGY study
Patients with COPD benefit from the Chiesi extrafine fixed triple combination ICS/LABA/LAMA: highly effective and easy to use.
An extrafine ICS/LABA combination decreases COPD exacerbations more than
Chiesi To Acquire 3 Hospital Products
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
Europe approves Holoclar®, the first stem cell—based medicinal product